How many patients are switching to biosimilars? – Healthcare Economist
That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions:
- What share.
What is HEMA? – Healthcare Economist
The Pink Sheet reports on a new international health technology assessment (HTA) body: Health Economics Methods Advisory group (HEMA).
The Health Economics Methods Advisory group (HEMA) is.
Links
- When is a public health problem a crisis?
- LA has the worst quality roads.
- CERN explained.
- IV fluid shortage.
- Too many 3-pointers.
Disclaimer :
This article is solely for informational purposes, any medical information contained.
Health economic value of postacute oral nutritional supplementation in older adult medical patients at risk for malnutrition – Healthcare Economist
That is my recent paper with co-authors Shanshan Wang, Jason Shafrin, and Kirk Kerr in BMJ Open. The abstract is below:
Objective To estimate the health economic value of.
Speculation on RFK Jr. as HHS Secretary – Healthcare Economist
From Tyler Cowen at Marginal Revolution:
One of the problems with an RFK Jr. ascendancy is that his core views, which run strongly against vaccines and pharmaceuticals, make it.
There is no placebo effect…but we still need them! – Healthcare Economist
That is the argument from an interesting post on the Carcinisation website titled “A Case Against the Placebo Effect“. In short, the authors argue that placebos in-and-of-themselves.
Do Treatment Sequencing / Pathways Models Have a Place in Health Technology Assessment? – Healthcare Economist
That is the title of an ISPOR Europe panel I saw with Hugo Pedder, Jeroen Jansen, Dawn Lee and Mark Harries. The goal of sequential pathways model is to be able to.
Health care in Spain – Healthcare Economist
ISPOR Europe kicks off this week in Barcelona, Spain. In honor of ISPOR, I will summarize some key attributes of the Spanish health care system based on.
Will AI help patients appeal insurance denials? – Healthcare Economist
It looks like the answer is ‘yes’. KFF reports that Holden Karau, a software engineer from the San Francisco Bay Area, created an AI tool to help.